Latest news with #ITM
Phone Arena
04-07-2025
- Phone Arena
The promised Galaxy S26 battery boost could turn out to be an epic fail
The list of things that could surprise me gets shorter by the day. It could be because we're living in 2025 – what the ancient Chinese would call "interesting times", or it could be just me. But, my stoicism gets challenged big time (once again) by Samsung and the decisions the company makes for their upcoming flagship Galaxy I wasn't surprised when I learned about these two prospects:After all, it's not like we've anticipated anything different from Sammy for the foreseeable future, judging by the recent past – none of the Galaxy flagships (foldable or not) deliver big mAh (battery capacity) numbers. At least not when compared to Xiaomi, OnePlus phones, for out of the blue, this report surfaced: Is Samsung finally cracking the code on Galaxy S26 battery woes? My hopes took off, only to crash shortly after. And what seems like a potential win, I see as a missed opportunity. Will Samsung go after a wasp waist again? | Image credit – PhoneArena OK, so: for the Galaxy S26, Samsung could team up with South Korea's ITM Semiconductor to improve battery life and make the batteries more goal is to create batteries that last longer and can potentially charge faster, thanks to new protective technology. ITM is said to be developing special battery protection circuits using something called epoxy molding compound (EMC), which helps control how the battery charges and technology adds a protective layer to block moisture, reduce interference from other parts inside the phone, and help keep the battery cool – all of which are key to preventing battery wear and heat is one of the biggest factors that shortens battery life, this new approach could make a difference, especially during heavy use like gaming or fast charging. The improved circuits are also getting smaller, which could free up space inside the phone and allow Samsung to fit in a larger battery. However, the report doesn't mention anything about the Galaxy S26 getting a larger capacity battery in addition to the EMC tech. And, not to play Cassandra here, but I think I know what's going to happen: Samsung will be extremely tempted to slim down the Galaxy S26 and if the EMC tech allows it, they'll do it. The way I see it, the Galaxy S26 will get the same ~3,900mAh capacity battery (from the Galaxy S25), but it will be presented as a major tech breakthrough ("See, we're innovating!") and a slim profile thanks to the EMC tech. I don't know if Samsung knows this, but people are not that crazy about super thin phones: Samsung Galaxy S25 Edge has a major problem: it does not sell Or, at least, they're not that crazy about the S25 Edge in particular. We'll see how the iPhone 17 Air performs, but I think we can all see where the iPhone 17 Air is headed, as my colleague Abdullah put it elegantly not so long ago. The Galaxy S25. | Image credit – PhoneArena Instead, what Samsung should do is not obsess with wasp waists, embrace a larger battery and then apply the EMC tech, potentially surpassing its rivals, if the new technology turns out to be that effective. Even if that doesn't allow for the Galaxy S26 to be slimmed down, I think Samsung should bite the bullet and just go with it. Think about it: would you have a marginally thinner phone with a mediocre battery cell, or a standard-sized chassis that houses a superior battery? The good news is that if you're on Team A, there's the Galaxy S25 Edge for you: it's thin, it's sleek, it's all about looks. Also, Samsung needs to hop on the silicon-carbon bandwagon as soon as possible. Such batteries can hold more charge in the same physical space, giving phones higher capacity without making them larger or heavier. Devices like the OnePlus 13 (6,000 mAh) already use this battery technology, offering higher mAh ratings while keeping a slim, compact design. As battery technology continues to advance, even bigger capacities are expected, with early rumors suggesting that the yet-to-be-announced OnePlus 15 could feature a 7,000mAh battery. The Galaxy S25 Ultra successor might not come with upgrades. | Image credit – PhoneArena As I mentioned above, the situation with the Galaxy S26 Ultra ("the best of the best" by Samsung) and the Galaxy Z Fold 7 (the maxed-out innovative foldable) also seems to be in dire Ultra flagship will apparently inherit the 5,000 mAh battery from its predecessors. That's the exact same capacity that Samsung has been putting in its Ultra flagships for six consecutive years, starting with the Galaxy S20 Ultra. Now, chipsets get more power efficient, there are software optimizations on board and, let's be frank about it, five thousand mAh of capacity is nothing to whine about. But a company needs to check itself against what happens to your reputation, if you were able to put a 5,000 mAh capacity battery cell in your flagship in 2020, but can't seem to up that number in 2026? That's a shame. The iPhone 16 Pro Max successor might get things right. | Image credit – PhoneArena Hold on to your hats, because we have something at our hands that is nothing short of a pure miracle: Apple (of all companies) might also embrace the big mAh numbers for its next flagship: It's not the whole iPhone 17 line that's apparently going to get its mAh numbers boosted – just the iPhone 17 Pro Max. Allegedly, the biggest and baddest iPhone of 2025 could sport a 5,000 mAh cell. On its own, that's nothing special, you'd think, but given Apple's software optimizations, that could very well mean the battery life could be great on this expensive phone. The Nothing Phone (3). | Image credit – PhoneArena The Nothing Phone (3) – the first flagship by Carl Pei's industry disruptor company – also steps in the 5,000 mAh+ territory. The cool-looking Phone (3) packs a 5,150 mAh cell with 65W charging speeds that will get you from 0% to 50% in less than 20 minutes. What's more, its cell is a silicon-carbon one, which leaves Samsung, a company with – I dare to say – a slightly bigger budget, practically without excuses. So, the Galaxy S26 is still (more than) half a year ahead in time. Let's hope some positive rumors appear in the months to come – as they say, hope springs eternal in the human breast. Secure your connection now at a bargain price! We may earn a commission if you make a purchase Check Out The Offer
Phone Arena
02-07-2025
- Phone Arena
Is Samsung finally cracking the code on Galaxy S26 battery woes?
Lately, Samsung fans have had to face a certain level of disappointment when it comes to battery upgrades. But it seems that with the Galaxy S26, the company may be working to address some of the issues by improving battery tech, allowing for bigger batteries, and even potentially faster charging. Reportedly, Samsung has started an agreement with South Korea's ITM Semiconductor Co. The agreement is said to be focused on finding specialized solutions to extend the longevity of batteries for the Galaxy S26 series. These solutions may include the use of additive filters to reinforce batteries, to protect them against physical stressors. According to The Elec, ITM Semiconductor is tasked to offer "battery protection circuits" made using epoxy molding compound, otherwise known as EMC technology. The report, coming from South Korea, also indicates these new circuits will regulate the flow of charge: so the Galaxy S26 's batteries will be protected from overcharging or discharging too quickly. EMC basically deploys a thin layer of polymeric compounds to block moisture and prevent electromagnetic interference from other components. This also helps dissipate heat generated by charging or discharging. Batteries degrade faster when subjected to heat while charging or battery-intensive tasks that discharge the battery too quickly (like gaming). The report also indicates that a less advanced tech solution is employed by ITM for the Galaxy A, Z Fold, and Z Flip series. Meanwhile, EMC is a more advanced technology and its protection circuits are smaller and become smaller with each iteration. When we're talking about phones, we all know how important every little half-inch of space could be. If these components get smaller, this allows for more space for the actual battery (hence, potentially a bigger battery). Galaxy S25 Plus. | Image Credit – Samsung The report from The Elec doesn't mention battery sizes. However, there have been rumors about Samsung potentially increasing the battery capacity, at least for the Galaxy S26 Ultra. However, more reliable insiders claimed the Ultra may not get above 5,400mAh battery cell, which is roughly less than a 10% increase over this year's Ultra model, the Galaxy S25 Ultra. Also, there was a report indicating the entire series may get bigger batteries, but nothing more than what some Chinese phone brands managed to get. A huge portion of Chinese phone makers are now using SiC batteries (silicon-carbon). Samsung is yet to join this pack, and for now, it seems that the company doesn't have plans to use the new tech in upcoming models. SiC batteries allow for a higher charge density, which means the battery has more capacity without becoming bigger physically. The OnePlus 13, for one, as well as the Nothing Phone (3) come with this type of battery. These phones have higher mAh ratings without being huge or bulky at all. Of course, the tech is evolving and batteries will grow even more. Rumors about the OnePlus 15, which has not been announced yet, claim that it may come with a 7,000mAh battery. When you think of things like that, the Galaxy S26 Ultra 's rumored 5,500mAh battery cell starts looking even smaller. However, the rumored improved protection could potentially allow for faster charging, another area where phones from China typically beat both Samsung and Apple. However, no reports indicate this at this moment. Personally, I'd love for Samsung to adopt SiC batteries or to figure out a way to put more mAh into the Galaxy S26 series. When you compare them with some Chinese phones in terms of battery capacity, the Galaxies seem to fall behind (I'm not even mentioning Apple here, for obvious reasons). Maybe Samsung will shine even brighter if, next year, there's a notable upgrade in battery sizes. But we'll have to wait and see for that. Secure your connection now at a bargain price! We may earn a commission if you make a purchase Check Out The Offer
Associated Press
23-06-2025
- Business
- Associated Press
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous. ITM-91/ITM-94 is a first-in-class, peptide-based theranostic pair combining the radiotherapeutic compound ITM-91 (Debio 0228) ([177Lu]Lu-DPI-4452), with the diagnostic agent ITM-94 (Debio 0328) ([68Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CAIX). CAIX is a cell surface protein that plays a key role in the tumor microenvironment, promoting tumor growth, survival, invasion and metastasis. In September 2024, ITM gained the exclusive worldwide license from Debiopharm for the development and commercial rights of ITM-91/ITM-94. The initiation of this study arm represents a significant advancement for ITM and Debiopharm following their licensing agreement. In the now initiated Part D of the trial, ITM-94 is being evaluated for its effectiveness to accurately classify an indeterminate renal mass as ccRCC or non-cancerous, when compared to CT/MRI imaging and histopathology. Secondary endpoints include sensitivity, specificity, and the positive and predictive value of ITM-94 PET/CT imaging compared to histopathology. This study arm is expected to enroll approximately 36 patients at around 15 clinical sites across the EU, US and Australia. ' The early results from the Gallium-68 CAIX PET/CT diagnostic are remarkable to date. I believe ITM-94 has the potential to change the way urologists and oncologists diagnose and stage patients with clear cell renal cell carcinoma, improving accuracy and reducing the need for biopsies. I have not seen a tracer with a similar profile since the PSMA PET/CT was established,' added Prof. Michael Hofman, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Peter MacCallum Cancer Centre, Melbourne, Australia. ' Clear cell renal cell carcinoma is the most common form of kidney cancer, with more than 90% of cases overexpressing the CAIX encoding gene. As survival rates are highly dependent on the stage of progression, rapid and precise diagnosis is essential to provide patients with the best possible treatment options and therapeutic outcomes. ITM-94 has already demonstrated potential exceptional imaging qualities, including high tumor-to-background ratios and detecting lesions not visible by CT scan with a potential favorable safety profile. We look forward to exploring the full potential of the theranostic pair ITM-91/ITM-94 across this trial to characterize and treat CAIX expressing cancer cells, advancing the efficacy of targeted radiopharmaceutical therapies,' said Dr. Celine Wilke, Chief Medical Officer of ITM. ' With high-quality imaging and high tumor uptake, ITM-94 has already demonstrated potentially significant diagnostic capabilities in solid tumors. The data gathered in Part D of the trial will be instrumental to the further validation of this theranostic pair. We highly value our partnership with ITM, which will continue to advance the rapid progression of these novel radio-diagnostics and -therapeutics through the clinic,' said Angela Zubel, Chief Development Officer, Research & Development at Debiopharm. About the Phase 1/2 ITM-91/ITM-94 Trial The five-part clinical trial (NCT05706129) is designed to assess the safety and tolerability, imaging characteristics, and efficacy of the theranostic pair ITM-91/ITM-94 in patients with unresectable, locally advanced or metastatic solid tumors. In Part A of the trial, ITM-94 demonstrated exceptional tumor imaging characteristics, with a high tumor-to-background ratio and a favorable tolerability profile in patients with confirmed ccRCC, with results published in the Journal of Nuclear Medicine. Part B, which is ongoing, is assessing escalating doses of the therapeutic agent, ITM-91, in patients whose tumors show high uptake of the imaging tracer. Based on the recommended dose from Part B, Part C of the trial will assess the safety and preliminary efficacy of ITM-91 in patients with ccRCC, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma and potentially other tumor types. In addition to the newly initiated Part D, Part E will assess ITM-94 uptake in other tumors. ITM will assume full sponsorship of the program from Debiopharm once the transfer is completed. About ITM-91/ITM-94 (Debio 0228/ 0328) ITM-91/ITM-94 is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and now exclusively licensed to ITM. ITM-94 ([68Ga]Ga-DPI-4452) is a PET imaging agent that may be used independently and is designed to identify patients whose cancers overexpress CAIX. Once identified, these patients may be treated with the lutetium-labelled radioligand, ITM-91 ([177Lu]Lu-DPI-4452), which delivers targeted radiation to the tumor with the aim to destroy it from the inside. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit We are on X. Follow us @DebiopharmNews at or on LinkedIn. ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected] Debiopharm Contact Dawn Bonine - Head of Communications [email protected] Tel: +41 (0)21 321 01 11 Attachment
Associated Press
16-06-2025
- Business
- Associated Press
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL's High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope. 'ITM and ILL's longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,' commented Dr. Andrew Cavey, CEO of ITM. 'Our priority access to ILL's renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.' The high neutron flux of ILL's reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production. Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. About the ILL, Institut Laue-Langevin The ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research communities. ITM Contact Corporate Communications Kathleen Noonan / Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected] ILL Contact Radionuclide Production Ulli Köster Phone: (+33) (0)4 76 20 71 54 Email: [email protected] Communications Catarina Espirito Santo Phone: (+33) (0)4 76 20 71 07 Email: [email protected] Attachment
Yahoo
16-06-2025
- Business
- Yahoo
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL's High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope. 'ITM and ILL's longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,' commented Dr. Andrew Cavey, CEO of ITM. 'Our priority access to ILL's renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.' The high neutron flux of ILL's reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production. Dr. Ken Andersen, Director of the Institut Laue-Langevin added, 'ILL operates the world-leading neutron source for research by neutron scattering and in nuclear and particle physics. Moreover, ILL's reactor provides irradiation positions at exceptionally high neutron flux that are exploited both for fundamental research and the production of radionuclides for medical applications. ILL is proud of the longstanding collaboration with ITM, regularly performing irradiations of Ytterbium-176 targets for ITM over the last 15 years, and looks forward to an even closer partnership in the coming years.'About Radiopharmaceutical Therapy (RPT)Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. the ILL, Institut Laue-LangevinThe ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research ContactCorporate CommunicationsKathleen Noonan / Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ ContactRadionuclide ProductionUlli Köster Phone: (+33) (0)4 76 20 71 54Email: koester@ Espirito SantoPhone: (+33) (0)4 76 20 71 07Email: communication@ Attachment 20250616_ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
